Skip to content
OpenCapital
Get started

Protagonist Therapeutics PTGX Q1 2026 earnings

Reported May 5, 2026 · After market close

Revenue$56.4MBeat by $44.7M
EPS$0.05Beat by $0.70
Revenue estimate$11.7M
EPS estimate-$0.65

Next report

Aug 5, 2026 (In 1 week)
Revenue estimate$199.8M
EPS estimate$2.11

Financials

Q1 2026

Income statement

See full
Revenue$56.4M+99.0%
Operating income-$3.6M+81.1%
Net income$3.8M+132%
EPS (diluted)$0.05+126%

Balance sheet

See full
Cash & equivalents$193.7M+38.7%
Total debt$9.8M-13.9%
Total equity$655.5M-4.9%
Total assets$697.5M-6.0%

Cash flow

See full
Operating cash flow-$48.9M-139%
CapEx$215.0K-60.6%
Free cash flow-$49.2M-139%

Valuation & ratios

Valuation

as of 07/28/26
See full
Market cap$8.72B+150%
Enterprise value$8.53B+156%
P/S117.7×+101×

Profitability

See full
Operating margin-192.4%-205pp
Net margin-154.9%-182pp

Returns & leverage

See full
Return on equity-17.1%-26.1pp
Debt / equity0×0.0×
Current ratio17.8×+0.5×

Segments

By segment

See full
Single Reportable$56.4M+99.0%

Versus estimates

Revenue

Q1 2026$56.4MBeat by $44.7M
Q4 2025$7.4MMiss by $1.3MQ3 2025$4.7MMiss by $10.2MQ2 2025$5.5MMiss by $2.9MQ1 2025$28.3MBeat by $21.8MQ4 2024$170.6MBeat by $89.6M

Diluted EPS

Q1 2026$0.05Beat by $0.70
Q4 2025-$0.69Miss by $0.16Q3 2025-$0.62Miss by $0.03Q2 2025-$0.55Miss by $0.02Q1 2025-$0.19Beat by $0.31Q4 2024$1.98Beat by $1.92

Ask the moment Protagonist Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Protagonist Therapeutics report Q1 2026 earnings?
Protagonist Therapeutics (PTGX) reported Q1 2026 earnings on May 5, 2026 after market close.
What were Protagonist Therapeutics's Q1 2026 revenue and EPS?
Protagonist Therapeutics reported revenue of $56.4M and eps of $0.05 for Q1 2026.
Did Protagonist Therapeutics beat estimates in Q1 2026?
Revenue beat the consensus estimate of $11.7M by $44.7M. EPS beat the consensus estimate of $-0.65 by $0.70.
How did Protagonist Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 99.0% from $28.3M a year earlier.
Where can I find Protagonist Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001104659-26-055629) and the 10-Q periodic report (0001104659-26-055661) directly on SEC EDGAR. The filing index links above go to sec.gov.